- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02759250
A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)
August 7, 2018 updated by: argenx
A Pilot, Phase Ib Feasibility Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)
To characterize the safety profile of ARGX-110 administered as mono- or combination therapy to patients with NPC at various stages of its natural history (adjuvant vs. metastatic).
Study Overview
Study Type
Interventional
Enrollment (Actual)
11
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Gent, Belgium
- UZG - Universitair Ziekenhuis Gent
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- Age ≥18 years.
- Written informed consent prior to any study-related procedure
- Willing and able to comply with protocol-specified procedures and scheduled evaluations
- Pathological diagnosis of nasopharyngeal carcinoma (NPC)
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1or 2
- Absolute neutrophil count (ANC) > 0.5 x 109/L
- Haemoglobin > 80 g/L
- Platelet count ≥ 50 x 109/L
- Total bilirubin ≤ 2 x the upper limit of normal (ULN)
- Alanine transaminase (ALT) ≤ 5 x ULN
- Serum creatinine ≤ 2 x ULN
Exclusion criteria:
- History or clinical evidence of neoplastic central nervous system (CNS) involvement. Note: Irradiated brain metastases that have been stable for > 1 month and do not require systemic glucocorticoid administration are allowed
- Major surgery within 4 weeks of ARGX-110 first dose administration
- Unresolved grade 3 or 4 toxicity from prior therapy (except mucositis from local radiation therapy).
- Active, untreated viral, bacterial, or systemic fungal infection
- Childbearing potential unless using an adequate measure of contraception
- Pregnancy or lactation. History of hypersensitivity to recombinant proteins
- Any clinical finding, including psychiatric and behavioural problems, which, in the opinion of the Investigator, precludes the patient from safely participating in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: adjuvant monotherapy
ARGX-110 5mg/kg once every three weeks for a maximum of 18 cycles
|
|
Experimental: metastatic/recurrent monotherapy
ARGX-110 5mg/kg once every three weeks until disease progression
|
|
Experimental: metastatic/recurrent combination therapy
ARGX-110 5mg/kg once every three weeks plus chemotherapy until disease progression.
The choice of the chemotherapy agents is limited to: cisplatin, carboplatin, 5-fluorouracil, gemcitabine and paclitaxel.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and grading of AEs
Time Frame: measured at screening, Day 1, Day 8, Day 15, Day 42, thereafter every 42 days until Day 378
|
Change from baseline in incidence and grading of AEs according to the Common Terminology Criteria for Adverse Event (NCI-CTCAE) Version 4.03
|
measured at screening, Day 1, Day 8, Day 15, Day 42, thereafter every 42 days until Day 378
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic profile of ARGX110 by Cmax
Time Frame: measured at Day 1 pre and post dose, Day 8, Day 15, Day 42 pre and post dose and thereafter every 42 days until Day 378
|
Change from baseline in Measurement of drug concentration in the blood
|
measured at Day 1 pre and post dose, Day 8, Day 15, Day 42 pre and post dose and thereafter every 42 days until Day 378
|
Pharmacokinetic profile of ARGX110 by AUC
Time Frame: measured at Day 1 pre and post dose, Day 8, Day 15, Day 42 pre and post dose and thereafter every 42 days until Day 378
|
Change in Measurement of drug concentration in the blood
|
measured at Day 1 pre and post dose, Day 8, Day 15, Day 42 pre and post dose and thereafter every 42 days until Day 378
|
Biomarkers CD70 immunohistochemistry (IHC)
Time Frame: measured at Screening, Day 42, and thereafter every 42 days until day Day 378
|
Change in Measurement of concentration in tumor tissue
|
measured at Screening, Day 42, and thereafter every 42 days until day Day 378
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sylvie Rottey, MD, UZG - Universitair Ziekenhuis Gent
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2015
Primary Completion (Actual)
April 25, 2018
Study Completion (Actual)
June 1, 2018
Study Registration Dates
First Submitted
April 22, 2016
First Submitted That Met QC Criteria
May 2, 2016
First Posted (Estimate)
May 3, 2016
Study Record Updates
Last Update Posted (Actual)
August 8, 2018
Last Update Submitted That Met QC Criteria
August 7, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Nasopharyngeal Neoplasms
- Nasopharyngeal Carcinoma
Other Study ID Numbers
- ARGX-110-1401
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on ARGX-110
-
OncoVerity, Inc.Janssen Research & Development, LLC; argenxCompleted
-
OncoVerity, Inc.Janssen Research & Development, LLC; argenxCompletedMyelodysplastic Syndromes | Leukemia, Myeloid, AcuteSwitzerland, France
-
Janssen Research & Development, LLCargenxWithdrawnMyelodysplastic Syndromes | Leukemia, Myelomonocytic, ChronicUnited Kingdom, Switzerland, Italy, Germany, France, Spain, Australia, Turkey, Brazil, Russian Federation, Saudi Arabia
-
OncoVerity, Inc.Janssen Pharmaceutical K.K.; argenxCompleted
-
argenxCompleted
-
argenxCompletedBioavailability StudyNetherlands
-
OncoVerity, Inc.Janssen Research & Development, LLC; argenxActive, not recruitingLeukemia, Myeloid, AcuteCanada, United States, Poland, Switzerland, Germany
-
argenxQuintiles, Inc.CompletedPrimary Immune ThrombocytopeniaAustria, Belgium, France, Germany, Spain, Czechia, Hungary, Poland, Ukraine, United Kingdom
-
argenxActive, not recruitingPrimary Immune ThrombocytopeniaUnited States, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Turkey, United Kingdom, Ukraine
-
argenxRecruiting